"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...

CRISPR Therapeutics has a 12-month low of $38.20 and a 12-month high of $91.10. The firm has a market cap of $3.52 billion, a price-to-earnings ratio of -14.59 and a beta of 1.68.

ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

The new Express License service removes barriers to accessing this transformative gene editing technology for startups.An ...

CRISPR stands for Clustered Regularly Interspaced Short Palindromic Repeats. It is a component of bacterial immune systems that can cut DNA, and has been repurposed as a gene editing tool. CRISPR is ...

In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against other biotech stocks with the biggest upside potential. Improving Trends for Biotech ...

An Express License provides fast, simple and affordable access to the CRISPR/Cas9 patent portfolio ... including life sciences research tools, kits and reagents; discovery of novel targets for ...

At-home test kits offer a convenient way to monitor health conditions privately, using advanced technologies for accurate and ...